7 drugs projected to become blockbusters by 2023

Several drugs are slated to make their debuts in 2019, but only seven are projected to achieve blockbuster status within four years, according to a new report from analytic firm Cortellis.

A blockbuster drug is defined as one that reaches $1 billion in annual sales.

Below are the projected blockbusters and their projected 2023 sales:

1. Upadacitinib ($2.2 billion). The drug, manufactured by AbbVie, treats rheumatoid arthritis.

2. Zolgensma ($2.09 billion). The drug is manufactured by AveXiz and Novartis to treat spinal muscular atrophy.

3. Roxadustat ($1.97 billion). The drug treats anemia and is manufactured by AstraZeneca, FibroGen and Astellas.

4. Ultomiris ($1.93 billion). The drug treats Paroxysmal nocturnal hemoglobinuria, a rare blood disease that causes red blood cells to break apart. It is manufactured by Alexion.

5. Skyrizi ($1.74 billion). The drug treats psoriasis. It is manufactured by AbbVie and Boehringer Ingelheim.

6. AR101 ($1.17 billion). The biologic drug, manufactured by Aimmune, is designed to protect patients from severe allergic reactions if they are exposed to peanuts.

7. LentiGlobin ($1.12 billion). The drug, manufactured by Bluebird Bio, treats beta thalassemia, a blood disorder that reduces the production of hemoglobin.

More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy's legal win expected to lower cost of opioid addiction treatment

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months